Renin Angiotensin Aldosterone System Inhibition in Controlling Dementia-Related Cognitive Decline
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
With the rising prevalence of cognitive impairment worldwide, clinicians are facing important challenges managing dementia, particularly Alzheimer's disease, the most prevalent dementia subtype. Given that current treatments mainly offer symptomatic improvement, without altering disease progression, the challenge now is to identify and integrate new therapeutic strategies. Hypertension is increasingly recognized as a modifiable risk factor for mild cognitive impairment (MCI), the precursor of dementia. The renin angiotensin aldosterone system (RAAS) is central to blood pressure regulation and medications targeting RAAS inhibition are associated with reduced rates of both cognitive and functional decline in those with MCI and dementia. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers are widely prescribed anti-hypertensives acting on the RAAS, and there is growing evidence that they act centrally, possibly exerting their effects independent of their blood pressure lowering properties. The relationship is complex however, and given the risks associated with hypotension particularly in older adults, treatment with these agents may not benefit all. Additionally, current evidence is limited to preclinical and observational studies such that there is now a pressing need to confirm preliminary studies with properly conducted randomized control trials. Here, we review some of the salient and complex aspects of these observations to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · cited 1×
“While dual RAAS inhibition with an ACE-I, ARB, or DRI is still sometimes prescribed in the management of hypertension [76], the evidence suggests that dual treatment offers little additional benefit and may be detrimental [77].”
BackgroundSilent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313 · cited 1×
“Hypertension is strongly associated with their development, particularly in older adults with stroke risk factors and previous stroke disease [32, 33], and they are known to correlate with the development of cognitive impairment [34, 35].”
BackgroundForette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“That isolated systolic hypertension is associated with vascular dementia [74], and given the high prevalence of vascular or mixed AD-vascular dementia subtypes in older adults [3], this would seem appropriate.”
BackgroundPeters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., CobbS, J., Belanger, A., D'Agostino, R. B., & White, L. R. (1992) · Neurology · doi:10.1212/wnl.42.1.115 · Cited by 527
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Onder, G., Penninx, B. W., Balkrishnan, R., Fried, L. P., Chaves, P. H., Williamson, J., Carter, C., Bari, M. D., Guralnik, J. M., & Pahor, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08024-8 · Cited by 339 · cited 1×
“CACE-Is are associated with increased exercise tolerance [79] and, muscle strength [80] and may carry out their effects by reducing inflammation, improving endothelial function, and increasing muscle blood flow and glucose delivery [80].”
BackgroundMcGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub3 · Cited by 315 · cited 1×
“Although there is little convincing evidence that treatment of hypertension prevents the development of cognitive impairment [17], several different anti-hypertensive medications are associated with reduced rates of cognitive [18–20] and functional decline [18, 21, 22], in those with established dementia.”
BackgroundAβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Self-citationVariation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease
Kehoe, P. G., Russ, C., McIlroy, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., et al. (1999) · Nature Genetics · doi:10.1038/5009 · Cited by 260 · cited 1×
“Numerous genetic associations between the ACE gene and increased risk of AD have been proposed [39, 40].”
BackgroundSelf-citationDavies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212 · cited 1×
“Those treated with ARBs also have a significant reduction in the incidence and progression of AD compared to those taking ACE-Is or other cardiovascular drugs [15], although further analysis to adjust for protopathic bias reduced the overall protective effect [62].”
ResultSelf-citationLehmann, D. J., Cortina-Borja, M., Warden, D. R., Smith, A. D., Sleegers, K., Prince, J. A., van Duijn, C. M., & Kehoe, P. G. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi202 · Cited by 199 · cited 1×
“Numerous genetic associations between the ACE gene and increased risk of AD have been proposed [39, 40].”
BackgroundSelf-citationDong, Y.-F., Kataoka, K., Toyama, K., Sueta, D., Koibuchi, N., Yamamoto, E., Yata, K., Tomimoto, H., Ogawa, H., & Kim-Mitsuyama, S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173534 · Cited by 109
Rozzini, L., Chilovi, B. V., Bertoletti, E., Conti, M., Rio, I. D., Trabucchi, M., & Padovani, A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1523 · Cited by 93 · cited 3×
“Different anti-hypertensives are suggested to either prevent onset [15, 18], and or progression of cognitive impairment [13, 19], and multiple drugs including diuretics [23], calcium channel blockers [24, 25], beta-blockers [18], and agents targeting the renin angiotensin aldosterone system (RAAS); angiotensin convert…”
BackgroundCaptopril and Enalapril Improve Cognition and Depressed Mood in Hypertensive Patients
Braszko, Karwowska-Polecka, Halicka, & Gard (2003) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.2003.14.4.323 · Cited by 89 · cited 1×
“Recent observational studies suggest that CACE-Is in particular may improve activities of daily living [21] although effects on mood are less clear [21, 78].”
BackgroundA Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease
Belbin, O., Brown, K., Shi, H., Medway, C., Abraham, R., Passmore, P., Mann, D., Smith, A. D., Holmes, C., McGuinness, B., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101914 · Cited by 34 · cited 1×
“Thus, after numerous replication attempts and more recently, genome wide association studies, the importance of ACE is being diminished [50] although some suggest that it should not be dismissed outright as a candidate gene for AD [51].”
BackgroundSelf-citationZhang, Z., Deng, L., Yu, H., Shi, Y., Bai, F., Xie, C., Yuan, Y., Jia, J., & Zhang, Z. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.074 · Cited by 19 · cited 1×
“Additionally, the ACE D-allele may be a genetic risk factor for the development of aMCI suggesting that a high serum ACE level plays an important role in the incidence of aMCI [47].”
BackgroundAntihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 1×
“ACE-Is are also associated with increased mortality in patients with AD compared with ARBs [90], and ACE-Is may even increase dementia risk [91] suggesting that even if proven beneficial, RAAS inhibition may not be suitable for all patients.”
Background
Cited by
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
Pistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134
Kehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Self-citation
Metadata
- Authors
- O'Caoimh, R., Kehoe, P. G., & Molloy, D. W.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2014-10-27
- Volume
- 42
- Issue
- s4
- Pages
- S575-S586
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1826853831
- Cited by
- 35
- References
- 18
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.